Article title: Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs
Authors: Jesudian, A. B., Gagnon-Sanschagrin, P., Heimanson, Z. Bungay, R., Chen, J., Guérin, A., Bumpass, B., Borroto, D., Joseph, G., & Dashputre, A. A.
Journal: Journal of Medical Economics
Bibliometrics: Volume 26, Number 1, pages 1169–1177
DOI: https://doi.org/10.1080/13696998.2023.2255074
When this article was first published online, in Figure 2, there was a typo in the numerical breakdown of the Rifaximin treatment cohort inclusion criteria (i.e., Type 1 vs. Type 2).
The proportion of patients who received Type 1 care should be listed as N = 1,138 (78.4%) and those who received Type 2 care as N = 314 (21.6%).
